Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tobramycin in Hemodialysis
NCT03904836Phase 1Completed
- Sponsor
- Hôpital Maisonneuve-Rosemont
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tobramycin in Gram-negative bacterial infection, sponsored by Hôpital Maisonneuve-Rosemont. Primary endpoint: Ratio of maximum tobramycin concentration to minimal inhibitory concentration at 72 hours. Started Jan 2019; status: completed.
02
Drugs
tobramycin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT03904836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904836.